Insmed, Inc. $INSM Shares Sold by Aberdeen Group plc

Aberdeen Group plc decreased its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 24.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 234,622 shares of the biopharmaceutical company’s stock after selling 75,127 shares during the quarter. Aberdeen Group plc owned about 0.11% of Insmed worth $33,788,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Artisan Partners Limited Partnership grew its stake in Insmed by 3.0% during the 2nd quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company’s stock valued at $333,555,000 after acquiring an additional 97,073 shares in the last quarter. Norges Bank acquired a new position in shares of Insmed during the 2nd quarter worth approximately $194,728,000. Orbis Allan Gray Ltd purchased a new stake in shares of Insmed in the second quarter valued at approximately $153,389,000. Eventide Asset Management LLC grew its position in shares of Insmed by 1.3% in the second quarter. Eventide Asset Management LLC now owns 1,196,494 shares of the biopharmaceutical company’s stock valued at $120,411,000 after purchasing an additional 14,819 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Insmed by 59.9% in the second quarter. Marshall Wace LLP now owns 1,113,361 shares of the biopharmaceutical company’s stock valued at $112,049,000 after purchasing an additional 417,124 shares during the last quarter.

Insider Transactions at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of Insmed stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the sale, the insider directly owned 41,754 shares of the company’s stock, valued at approximately $7,315,300.80. The trade was a 67.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Elizabeth M. Anderson sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $204.58, for a total value of $1,022,900.00. Following the transaction, the director owned 58,729 shares of the company’s stock, valued at $12,014,778.82. This trade represents a 7.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 173,253 shares of company stock worth $29,629,842 over the last ninety days. Company insiders own 3.00% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on INSM shares. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. Rothschild & Co Redburn set a $263.00 price target on shares of Insmed in a research report on Thursday, December 4th. UBS Group dropped their price objective on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a report on Tuesday, January 6th. Mizuho set a $212.00 price objective on shares of Insmed in a research report on Thursday, December 18th. Finally, TD Cowen set a $241.00 target price on shares of Insmed in a research note on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Insmed has an average rating of “Buy” and an average target price of $204.24.

Insmed Stock Performance

Shares of INSM stock opened at $148.75 on Tuesday. The firm’s 50 day moving average price is $168.10 and its 200-day moving average price is $162.59. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The firm has a market cap of $31.72 billion, a P/E ratio of -24.03 and a beta of 1.11.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.